Avandia Safety Under The Microscope
This article was originally published in The Pink Sheet Daily
Executive Summary
Cardiovascular risks identified in a meta-analysis by Steven Nissen prompt immediate announcements of an advisory committee meeting and congressional investigations.
You may also be interested in...
Do Payers Pay More If Drug Risks Are Not Disclosed? GSK Seeks Supreme Court Answer
GlaxoSmithKline petitions court to review third party payers' RICO claims in Avandia litigation; PhRMA cites 'growing torrent' of such suits against drug makers.
GSK’s Tanzeum Launch Marks The Big Pharma’s Return To Diabetes
GSK expects Tanzeum will be one of its “core big six” drugs despite the fact that it is the fourth GLP-1 to market. VP-General Medicines Cheryl MacDiarmid discussed GSK’s return to diabetes in an interview.
Avandia Day Two Might Be Same Old Song Even With Broken RECORD
There may be more at stake for FDA, and the pharmaceutical industry in general, in how the advisory committees interpret the RECORD trial than there is for Avandia itself.